71 results
The main objective is assessment of safety and feasibility of intravenous administration of autologous, in vitro expanded, mesenchymal stem cells in patients with pulmonary arterial hypertension due to systemic sclerosis. The secondary objective is…
To determine the efficacy and the safety of PREOB®, a proprietary population of autologous bone-forming cells, in the treatment of non-infected hypotrophic non-union fractures of long bones.
To show immunologic efficacy of tumor-peptide loaded natural DC in mCRPC patients. Further we will demonstrate that natural DC vaccinations are safe, feasible and clinically effective. Also the therapy effect on quality of life will be studied.
Primary ObjectiveTo demonstrate that the effectiveness of the NOVOCART® 3D plus autologouschondrocyte transplantation system is superior to microfracture for the treatment ofarticular cartilage defects of the knee by demonstrating superiority of the…
In this phase I/II clinical study will assess the safety, effectiveness and homing of asCTMP, namely autologous mesoangioblasts, that will be injected 3x intra-arterially in right lower leg via catheter in 5 indivuals that carry the m.3243A>G…
The objective of the present trial is to investigate the safety of an allogenic tumor cell lysate loaded onto autologuous dendritic cells (AlloDen) in patients with malignant mesothelioma (MM). Heretoo we will perform a phase I study with a…
This is an interventional study and the primary objective is the immunogenicity of combined pDC and myDC vaccination. The secondary objectives are the biodistribution, the safety, quality of life and overall survival.
Determine the safety and efficacy of Tiscover compared to AS210 (acellular donor dermis, construct Tiscover is cultured on) for the treatment of chronic, therapy resistant (arterio-) veneus leg/foot ulcers in an out patient setting.
The primary objective is the safety and feasibility of CEA/frameshift derived neopeptide loaded DC in patient with MSI-positive colorectal cancer and persons who are known to be carrier of a germline MMR-gene mutation with no signs of disease yet.…
A 6-month study of efficacy and safety comparing concentration-controlled Certican® with MSCs to Certican® with standard tacrolimus in renal transplant recipients
This is an exploratory study and the primary objective is the immunogenicity and feasibility of combined chemotherapy-DC vaccination. The secondary objectives are the toxicity and clinical efficacy. This study will provide important data on the…
ObjectiveEvaluation of the application of cultured autologous keratinocytes in combination with a meshed split skin autograft to improve burn wound healing
> Primary Objective:This is a pilot study, aiming at the clinical evaluation with respect to safety and feasibility of a one-step surgical procedure for maxillary sinus floor augmentation for the placement of dental implants, using a ceramic…
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for multiple antigens to induce an immune response. The secondary objective is to show clinical response.
The primary goal is to show the capability of monocyte-derived DC after RNA electroporation for melanoma antigens to induce an immune response.The secondary objective is to show clinical response.
To test the safety and feasibility of intravenous administration of autologous BM-MSC after one-sided LVRS and prior to a second LVRS procedure for patients with end-stage pulmonary emphysema and to compare with historic lung function data of a…
Primary: 1 to test the safety and feasibility of autologous MSC therapy in HLA-DR mismatched patients with SCR in the renal biopsy 4 weeks after renal transplantation.Secondary1 To assess histologic changes before and after MSC treatment.2 To…
To improve the steady hematopoiesis post-ASCT by infusing the autologous transplant directly in the bone marrow compartment.(protocol page 6)
A pilot feasibility study (n=5) will be performed to evaluate the feasibility (logistics, timing) and safety of administering autologous tumor infiltrating lymphocytes (TIL) generated at the NKI-AVL infused in conjunction with systemic high-dose…
We expect to finalize the current phase I study by the May 2008 demonstrating that injection of tumor lysate-pulsed autologous DCs injected in patients with MM after chemotherapy is safe and well tolerated with induction of immune responses. New…